Abstract
A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 149-156 |
| Number of pages | 8 |
| Journal | Journal of Affective Disorders |
| Volume | 41 |
| Issue number | 2 |
| DOIs | |
| State | Published - Nov 25 1996 |
Fingerprint
Keywords
- Adolescent
- Child
- Extended evaluation
- Major depressive disorder
- Predicting response
ASJC Scopus subject areas
- Psychiatry and Mental health
- Behavioral Neuroscience
- Biological Psychiatry
- Neurology
- Psychology(all)
Cite this
The effects of extended evaluation on depressive symptoms in children and adolescents. / Rintelmann, Jeanne W.; Emslie, Graham J.; Rush, A. John; Varghese, Thomas; Gullion, Christina M.; Kowatch, Robert A.; Hughes, Carroll W.
In: Journal of Affective Disorders, Vol. 41, No. 2, 25.11.1996, p. 149-156.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effects of extended evaluation on depressive symptoms in children and adolescents
AU - Rintelmann, Jeanne W.
AU - Emslie, Graham J.
AU - Rush, A. John
AU - Varghese, Thomas
AU - Gullion, Christina M.
AU - Kowatch, Robert A.
AU - Hughes, Carroll W.
PY - 1996/11/25
Y1 - 1996/11/25
N2 - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.
AB - A sample of 137 child and adolescent outpatients with major depressive disorder were examined to identify baseline clinical characteristics that predicted symptom severity at the end of a 3-week evaluation period and to determine whether change in symptom severity between week 1 and week 2 predicted symptom severity at week three. Subjects underwent three consecutive weekly evaluations prior to being considered for entry into a double-blind, placebo-controlled treatment trial of fluoxetine, Results indicated that the combination of age, social functioning, family history, Children's Depressive Rating Scale-Revised (CDRS-R) (Poznanski et al, (1985) Psychopharmacol. Bull. 21, 979-989) total score at visit one, and percent change in symptom severity between visit one and visit two were predictors of symptom severity at visit three. These findings suggest that (1) subjects should not be excluded from randomized controlled clinical treatment trials based solely on improvement of symptom severity between visits and (2) an extended evaluation period is warranted, especially for adolescents whose symptom severity tends to fluctuate from week to week.
KW - Adolescent
KW - Child
KW - Extended evaluation
KW - Major depressive disorder
KW - Predicting response
UR - http://www.scopus.com/inward/record.url?scp=0030602263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030602263&partnerID=8YFLogxK
U2 - 10.1016/S0165-0327(96)00084-5
DO - 10.1016/S0165-0327(96)00084-5
M3 - Article
C2 - 8961043
AN - SCOPUS:0030602263
VL - 41
SP - 149
EP - 156
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
SN - 0165-0327
IS - 2
ER -